Literature DB >> 22184400

The future of drug development in urothelial cancer.

Robert Dreicer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22184400     DOI： 10.1200/JCO.2011.39.5566

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

2.  Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Authors:  Ashish M Kamat; Joaquim Bellmunt; Matthew D Galsky; Badrinath R Konety; Donald L Lamm; David Langham; Cheryl T Lee; Matthew I Milowsky; Michael A O'Donnell; Peter H O'Donnell; Daniel P Petrylak; Padmanee Sharma; Eila C Skinner; Guru Sonpavde; John A Taylor; Prasanth Abraham; Jonathan E Rosenberg
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

3.  Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.

Authors:  Sheng Zhang; Hongxi Xue; Qiang Chen
Journal:  Oncotarget       Date:  2016-09-06

4.  Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy.

Authors:  Vinita Agrawal; Niharika Bharti; Rakesh Pandey
Journal:  Arab J Urol       Date:  2020-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.